Protocol Ledger

NCT03536767 · Phase II · TERMINATED

Open-Label Study of AG10 in Patients With Cardiomyopathy

Interventional Phase II clinical trial protocol NCT03536767 sponsored by Eidos Therapeutics, a BridgeBio company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-08 Enrollment: 47 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03536767
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)47 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03536767
Protocol FieldVerified Registry Value
NCT IdentifierNCT03536767
Consolidated Lead SponsorEidos Therapeutics, a BridgeBio company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment47 participants (ACTUAL)
Registered Start Date2018-08-08
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI